Video

ReciBioPharm Capacity Update July 2025: Analytical Services

Source: ReciBioPharm

ReciBioPharm is a CDMO specifically established to focus on serving companies seeking to develop and commercialize advanced therapy medicinal products (ATMPs). ReciBioPharm’s specialized CDMO capabilities include pre-clinical to clinical and commercial development and manufacture for new biological modalities encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

This session shares:

  • Benefits of choosing a CDMO with complete end-to-end services and in-house analytical capabilities
  • Current analytical offerings for LBP and LNP products with a few method highlights
  • Capping efficiency and dsRNA

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

ReciBioPharm